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Abstract 
Active neurons increase their energy supply by dilating nearby arterioles and capillaries. This 
neurovascular coupling underlies BOLD functional imaging signals, but its mechanism is 
controversial. Canonically, neurons release glutamate to activate metabotropic glutamate 
receptors (mGluR5) on astrocytes, evoking Ca2+ release from internal stores, activating 
phospholipase A2 and generating vasodilatory arachidonic acid derivatives. However, adult 
astrocytes lack mGluR5, and knock-out of the IP3 receptors that release Ca
2+ from stores 
does not affect neurovascular coupling. We now show that buffering astrocyte Ca2+ inhibits 
neuronally-evoked capillary dilation, that astrocyte [Ca2+]i is raised not by release from stores 
but by entry through ATP-gated channels, and that Ca2+ generates arachidonic acid via 
phospholipase D2 and diacylglycerol kinase rather than phospholipase A2. In contrast, 
dilation of arterioles depends on NMDA receptor activation and Ca2+-dependent NO 
generation by interneurons. These results reveal that different signalling cascades regulate 
cerebral blood flow at the capillary and arteriole levels. 
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Introduction 
Functional hyperemia is the phenomenon by which active brain regions induce a local 
increase in blood flow to match their energy demands, via a process termed neurovascular 
coupling. Traditionally, regulation of cerebral blood flow was thought to occur at the level of 
arterioles1-3, however, capillaries in the brain are also wrapped by contractile cells called 
pericytes4, which can respond to neuronal activity and control blood flow at a more local 
level than arterioles5,6. Although neurovascular coupling is the basis of blood oxygen level 
dependent (BOLD) functional magnetic resonance imaging (fMRI), an increasingly routine 
method used to measure brain activity in the clinic and in cognitive studies, our 
understanding of the underlying signalling mechanisms is still incomplete.  
Neurovascular coupling can partly occur as a result of direct signalling from neurons to 
the vasculature7. However, over the last decade, a role for astrocytes, which have endfoot 
processes near blood vessels, has also been demonstrated, whereby neurons signal to 
astrocytes, which in turn release vasoactive substances onto vessels8. Initial data 
suggesting astrocyte-mediated neurovascular signalling came from experiments in which 
stimulating neurons led to a rise in astrocyte [Ca2+]i as well as arteriole dilation
1. It was 
further shown that raising astrocyte [Ca2+]i evoked vascular dilations and constrictions
2,3,9, 
which were produced by metabolites of arachidonic acid (AA) generated by phospholipase 
A2 (PLA2). Dilation occurred via the formation of prostaglandin E2 (PGE2) and 
epoxyeicosatrienoic acids (EETs), while production of 20-hydroxyeicosatetraenoic acid (20-
HETE) resulted in constriction (see ref. 8 for review).   
Although these findings were obtained in several laboratories, controversies still 
abound. Astrocyte Ca2+ signals may be too small or slow10, or too infrequent11, to have a 
causative role in neurovascular coupling. However, these conclusions were based on 
measuring Ca2+ signals within astrocyte cell bodies, rather than in the fine processes12 of 
astrocytes near synapses which are presumably the first responders to neuronal activity. 
Indeed, recent in vivo studies have reported rapid, physiological stimulation-evoked [Ca2+]i 
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rises in astrocyte somata and endfeet in the somatosensory cortex13, and in the processes 
but not the somata of olfactory bulb astrocytes14.  
A second controversy concerns how elevations of astrocyte Ca2+ concentration are 
generated. While these were originally thought to reflect activation of mGluR5 and 
downstream IP3-dependent release of Ca
2+ from internal stores1-3, recent studies show that 
mGluR5 expression is downregulated in astrocytes from adult animals15. Furthermore, 
animals lacking IP3R2, the primary IP3 receptor in astrocytes, display unaltered 
neurovascular coupling16. Nevertheless, there are other mechanisms which could raise 
astrocyte [Ca2+]i, including Ca
2+ permeable AMPA receptors17, NMDA receptors18, ATP 
receptors19 and TRPA1 channels20, and thus mediate astrocyte to vessel signalling.  
Finally, it is unclear whether neurovascular coupling at the capillary level is mediated 
by the same pathways as that at the arteriole level. Although dilation of capillaries and 
arterioles both rely on relaxation of actomyosin, in pericytes and in arteriolar smooth muscle 
respectively, it seems plausible that local (capillary) and spatially broader (arteriolar) control 
of blood flow might be driven by different signalling pathways. 
Here, we investigated the role of astrocytes in mediating neurovascular coupling in the 
cerebral cortex, in brain slices and in vivo. We provide the first direct demonstration that a 
rise in astrocyte [Ca2+]i is necessary for neuronally-evoked capillary dilation to occur. We 
show that the source of Ca2+ involved in this process and its molecular effects are radically 
different from what was previously believed. We also show that arteriole dilation is not 
mediated by astrocyte Ca2+ signalling, but instead depends on NMDA receptor-mediated 
nitric oxide release (Supp. Fig. 1). 
 
Results 
Neuronal activity evokes capillary dilation  
We assessed whether cerebral cortical capillaries can respond to electrically 
stimulated synaptic activity in cortical slices from P21 (adolescent) rats. Stimulation-evoked 
fibre volley and field excitatory post-synaptic currents (fEPSCs) were recorded in all 
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experiments to confirm activation of the neuropil near the capillary being studied (Supp. Fig. 
2). Vascular responses are known to be modulated by the oxygen (O2) concentration in the 
tissue: physiological [O2] produced by bubbling the superfusate with 20% O2 results in larger 
dilations6,9,21. Therefore, all experiments reported here were conducted using 20% O2. 
Furthermore, since vessels in brain slices do not have resting tone due to a lack of 
noradrenergic signalling from the locus coeruleus, and a lack of perfusion pressure and 
blood flow, a vasoconstricting agent is required to provide the resting tone upon which 
neuronally-evoked dilations normally occur22. Here, we bath-applied the thromboxane A2 
analogue U46619 (200 nM) for at least 5 minutes to pre-constrict cortical vessels prior to 
neuronal stimulation. Capillaries were identified as vessels <10 µm wide that lack a 
continuous layer of smooth muscle22 (Supp. Fig. 2). U46619 constricted capillaries by 
18.7±0.7% (n=213 separate capillary regions (presumed locations of pericytes) in 112 
vessels from 70 animals: Fig. 1a-b; Supp. Fig. 3) within minutes, without affecting 
electrically-evoked synaptic activity (Supp. Fig. 2c-d), and this constriction was maintained 
for at least 30 min (Supp. Fig. 3a). Electrically-stimulated neuronal activity then dilated the 
capillaries by 14.5±0.5% (Fig. 1a, b).  
We first confirmed that stimulation-evoked capillary dilation resulted from neuronal 
activity and not direct stimulation of the vasculature. In the presence of tetrodotoxin (TTX, 
500 nM), stimulation-evoked neuronal activity (the fibre volley and fEPSCs) was completely 
abolished (Supp. Fig. 2c) and capillary responses were also absent (0.2±1.6% dilation, 
n=11; Fig. 1c, f) unlike for interleaved controls (14.0±1.6% dilation, n=7, significantly 
different, p=0.00008; Fig. 1f). Blocking ionotropic glutamate receptors showed that post-
synaptic activity was necessary for neurovascular signalling to capillaries. The AMPA/KA 
receptor blocker NBQX (10 µM) inhibited stimulation-evoked fEPSCs (Supp. Fig. 2c, d) and 
reduced capillary dilation by 82.2% (p=0.002; Fig. 1d, g). In contrast, the NMDA receptor 
blocker D-AP5 (25 μM) had no effect on stimulation-evoked capillary dilation (p=0.6; Fig. 1e, 
h). Thus, stimulation-evoked capillary dilation reflects action potential driven glutamatergic 
synaptic activity but does not depend on Ca2+ entry into neurons via NMDA receptors. 
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Capillary dilation is mediated by Ca2+-dependent astrocyte signalling  
We next investigated whether astrocyte Ca2+ signalling mediates neuron-to-capillary 
signalling. To address this, astrocytes near the vessel of interest were whole-cell patch-
clamped and dialyzed with either a control internal solution containing 1 mM EGTA (ethylene 
glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid) or one containing 30 mM of the 
faster Ca2+ chelator BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid). 
Spread of the pipette solution between astrocytes via gap junctions was visualized using the 
dye Alexa Fluor 488 (40 μM). After 10-15 minutes of dialysis, the astrocyte network, 
including endfeet along the vessel of interest, was filled with Alexa Fluor 488 (Fig. 2a). 
Stimulating neuronal activity when astrocytes were dialyzed with the control (EGTA) internal 
solution evoked robust capillary dilations (16.2±1.7%, n=12; Fig. 2b, c). However, when 
astrocytes were dialyzed with BAPTA to buffer rises in [Ca2+]i, stimulation-evoked dilation 
was reduced by 64% to 5.9±2.0% (n=17, p=0.0007; Fig. 2b, c). The free [Ca2+]i in both the 
EGTA and BAPTA internal solutions was set to ~24 nM, so the effects observed are not 
attributable to differences in baseline free [Ca2+]i, implying that a transient rise in astrocyte 
[Ca2+]i in response to neuronal stimulation is, at least in part, necessary for neurovascular 
signalling to capillaries.  
In some experiments, we imaged vessels as the internal solution spread from the 
patch-clamped astrocyte into the endfoot processes, to observe whether buffering astrocyte 
Ca2+ rises had any effect on baseline capillary diameter. There was no significant change in 
the baseline diameter of the vessels when using either the control internal solution 
(2.0±1.8% constriction in 4 capillaries, not significantly different from zero, p=0.3) or the 
BAPTA internal (5.4±3.2% dilation in 8 capillaries; not significantly different from zero, p=0.1; 
diameter change in BAPTA was not significantly different from that in EGTA, p=0.2).  
P2X1 receptors raise astrocyte [Ca
2+]i 
Many mechanisms leading to a [Ca2+]i rise in astrocytes have been suggested. Group I 
metabotropic glutamate receptors (mGluR1/5)23 and the ATP receptor P2Y1
24 are both G-
protein coupled receptors (GPCRs) associated with Gq signalling that induces Ca
2+ release 
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from internal stores by generating IP3. In particular, mGluR1/5 receptors have long been 
thought to be the primary cause of astrocyte [Ca2+]i rises
23. Recently, group II mGluRs were 
also shown to raise [Ca2+]i within astrocytes via an as yet undefined mechanism
25. 
Furthermore, the Ca2+-permeable heteromeric ATP receptor P2X1/5
19 and transient receptor 
potential A1 (TRPA1) channels20 are also possible routes for Ca2+ influx into astrocytes. We 
tested the role of each of these receptors in mediating capillary-level neurovascular coupling. 
Stimulation-evoked capillary dilation was not reduced after bath application of a non-specific 
blocker of both group I and II mGluRs, (S)-MCPG (1 mM, p=0.1; Fig. 2d, i), the P2Y1 
receptor blocker MRS2179 (25 μM, p=0.8; Fig. 2e, j) or the TRPA1 blocker A967079 (10 μM, 
p=0.3; Fig. 2f, k). However, the P2X1 blockers NF449 (100 nM, Supp. Table 1) and NF023 (5 
μM) reduced the stimulation-evoked capillary dilation by 58% (p=0.0007; Fig. 2g, l) and 94% 
(p=0.001; Supp. Fig. 4d), respectively. Similar results were obtained using shorter 
stimulation durations than the 1 min used above (NF449 reduced dilation by 94% (p=0.005) 
and 60% (p=0.01) for 200 ms and 5 s stimulation, respectively; Supp. Fig. 4a-c), and in P45 
mice (66% reduction with NF449, p=0.00008 using 5 s stimulation; Supp. Fig. 4e). If P2X1 
receptors raise astrocyte [Ca2+]i to evoke the dilation, then we should also be able to evoke 
dilation simply by activating this receptor. Indeed, a 5 s puff application of ,β-methylene 
ATP (100 μM, see Methods), an agonist for P2X1
26, onto the neuropil induced a 10.7±2.3% 
dilation of cortical capillaries, whereas application of vehicle did not (0.4±1.3% constriction, 
significantly different, p=0.0007; Fig. 2h, m). These data suggest that capillary level 
neurovascular coupling occurs largely through a P2X1 receptor-dependent pathway in 
astrocytes. 
To study stimulation-evoked changes in [Ca2+]i within astrocyte endfeet, we whole-cell 
clamped astrocytes to selectively fill them with the membrane-impermeant Ca2+ indicator dye 
Fluo4 (50 μM), and a reference dye (Alexa Fluor 594, 40 μM) to allow ratiometric imaging 
(as R=(Fluo4 intensity)/(Alexa Fluor 594 intensity)). We observed spontaneous local Ca2+ 
transients in astrocyte cell bodies and processes, as previously reported27-29. Stimulating 
neuronal activity evoked an increase in [Ca2+]i in astrocytes (ΔR/R=41.4±11.7% in endfeet, 
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n=9, p=0.003 compared to zero; ΔR/R=58.4±20.2% in processes, n=23, p=0.006; 
ΔR/R=60.2±24.3% in somata, n=13, p=0.02; Fig. 3a-c). The amplitude of this signal was 
reduced by 81% and 85% in endfeet and processes, respectively, by the P2X1 receptor 
blocker NF449 (ΔR/R=7.9±3.1% in endfeet, n=6, p=0.02 compared to control data; 
ΔR/R=8.5±3.4% in processes, n=14, p=0.02; Fig. 3b, c). NF449 did not significantly block 
the calcium rise in somata (Fig. 3c). These data are consistent with P2X1 receptor-mediated 
signalling within astrocytes mediating the capillary dilations seen in Figs. 1 and 2. In 
contrast, the mGluR blocker (S)-MCPG (1 mM) did not alter the [Ca2+]i changes in the 
endfoot, process or somata (Fig. 3c). 
Arachidonic acid metabolites mediating capillary dilation 
Astrocyte-mediated neurovascular coupling is thought to occur via the synthesis of AA 
by Ca2+-activated phospholipase A2 followed by metabolism into vasoactive substances
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such as prostaglandins (by the activity of cyclooxygenase (COX)) or EETs (by the activity of 
epoxygenases). We tested the contribution of these enzymes using specific inhibitors. The 
COX1 inhibitor SC-560 (1 μM) reduced the stimulation-evoked capillary dilation by 64% 
(p=0.0002; Fig. 4a, d), but the COX2 inhibitor NS-398 (10 μM; Fig. 4b, e) and the 
epoxygenase inhibitor PPOH (25 μM; Fig. 4c, f) had no effect on the dilation. COX1 
generates several prostaglandin derivatives, including the vasodilators PGE2 and PGI2. 
Blocking the EP4 receptor for PGE2 with L-161,982 (1 µM) reduced the stimulation-evoked 
dilation by 72% (p=0.004; Fig. 4g, j). In contrast, blocking the IP receptor for PGI2 with 
CAY10441 (1 μM) did not affect the dilation (Fig. 4h, k). Nitric oxide (NO) has also been 
shown to contribute to arteriolar vasodilation in the cortex30,31, however, when the NO 
synthase inhibitor L-NG-nitroarginine (L-NNA; 100 μM) was applied, stimulation-evoked 
capillary dilation was not reduced (Fig. 4i, l), implying that NO does not contribute to capillary 
dilation in the cortex. Thus, PGE2 generated by COX1 and acting on EP4 receptors is the 
primary vasoactive signal mediating capillary dilation.  
We used immunohistochemistry to investigate the cellular location of the enzymes 
metabolising AA. We found COX1 labelling in processes along arterioles and capillaries that 
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co-labelled for aquaporin 4 (AQP4), a protein expressed highly in astrocyte endfeet (Supp. 
Fig. 5a). In contrast, COX2 did not colocalize with the astrocyte structural protein glial 
fibrillary acidic protein (GFAP), but was expressed diffusely in the neuropil with higher 
expression in neuronal somata (Supp. Fig. 5b). Antibodies against the CYP2C11 isoform of 
epoxygenase, reported to be the predominant epoxygenase in the rodent brains32, labelled 
AQP4-expressing endfeet along larger vessels, but not along capillaries (Suppl. Fig. 5c). 
Furthermore, antibodies against PGE2 synthase (PGES) also labelled GFAP-expressing 
astrocyte cell bodies, processes and endfeet (Supp. Fig. 5d). These findings are consistent 
with the functional data in Fig. 4 suggesting that PGE2 is the main vasoactive metabolite of 
AA that signals to capillaries, and is synthesized within astrocytes.  
PLD2, not PLA2, initiates neurovascular coupling at the capillary level 
The Ca2+-dependent enzyme PLA2 is thought to synthesize the AA which is converted 
into PGE2
2,8,33. We found that PLA2 immunolabelling colocalized with GFAP positive 
astrocyte endfeet along capillaries (Supp. Fig. 6), suggesting a possible role for this enzyme. 
Surprisingly, however, stimulation-evoked capillary dilation was unchanged when PLA2 was 
blocked with its inhibitor MAFP (10 μM, Fig. 5a, d). Thus, despite being in the correct cellular 
compartment, PLA2 is not the primary enzyme involved in the AA synthesis required for 
signalling to capillaries. We therefore sought other possible AA sources.  
The enzymes phospholipase C (PLC) and PLD can produce AA via a multi-step 
process. PLC breaks down PIP2 (phosphatidylinositol 4,5-bisphosphate) to DAG 
(diacylglycerol) and IP3, while PLD acts on membrane phospholipids to synthesize 
phosphatidic acid, which is then converted to DAG by phosphatidate phosphatase. DAG 
produced by PLC or PLD in this way can be further metabolized by DAG lipase (DAGL) to 
produce AA. A specific blocker of PLC, U73122 (10 μM), did not reduce stimulation-evoked 
capillary dilation (Fig. 5b, e). In contrast, a PLD specific blocker FIPI (1 μM) reduced dilation 
by 64% (p=0.0005; Fig. 5c, f), suggesting that PLD plays a major role in synthesising AA. 
Two isoforms of PLD are expressed in mammals, PLD1 and PLD2, both of which are 
regulated34,35 by Ca2+. A specific inhibitor of PLD1, VU0155069 (500 nM), had no effect on 
10 
stimulation-evoked dilation (Fig. 5g, j), however, a blocker of PLD2, CAY10594 (1 μM) 
completely abolished the capillary dilation (p=0.0002; Fig. 5h, k), suggesting that AA 
synthesis is PLD2 dependent. If so, then the downstream enzyme DAGL, which is required 
for AA production from DAG, should also be involved. Indeed, the DAGL inhibitor RHC80267 
(50 μM) also blocked the stimulation-evoked capillary dilation (reduced by 81%, p=0.0004; 
Fig. 5i, l), suggesting the PLD2-DAGL pathway as the mechanism for AA synthesis.  
We considered whether PLD2 might, instead of being in the pathway for AA synthesis, 
be activated downstream of the PGE2 receptor EP4 in pericytes to cause the capillary 
dilation. However, there was no difference between PGE2-induced dilation of cortical 
capillaries in the absence (8.1±1.7%) and presence (8.5±2.1%) of the PLD blocker FIPI 
(Supp. Fig. 7), supporting our conclusion that the PLD2-DAGL pathway is upstream of AA 
synthesis. 
Consistent with these results, immunolabelling for PLD1 showed that it is expressed 
diffusely in the neuropil and strongly in endothelial cells lining arterioles (Supp. Fig. 8a), but it 
was not in astrocyte endfeet, pericytes or capillary endothelial cells (Supp. Fig. 8a, b). In 
contrast, PLD2 immunolabelling occurred in GFAP-positive astrocyte endfeet on capillaries 
(Supp. Fig. 8c) and cell bodies (Supp. Fig. 8d), but not in pericytes or endothelial cells, 
consistent with a role in astrocyte-mediated neurovascular signalling to capillary pericytes.  
Arteriole dilation is mediated by a different signalling pathway  
To compare the data above on capillary dilation with the dilation of arterioles evoked 
by neuronal activity, we carried out similar experiments imaging arterioles. U46619 
preconstricted arterioles by 11.8±0.8% (n=36 arterioles from 26 animals, Supp. Fig. 9). The 
neuronal stimulation-evoked dilation of arterioles (7.0±0.7%, n=36, mean of all control data 
in Fig. 6) was smaller than that evoked in capillaries (12.1±1.9%, Supp. Fig. 4b, both with 5 s 
stimulation). Remarkably, in contrast to the capillary dilation, the arteriole dilation was 
unaffected by dialysing the astrocyte network with BAPTA (Fig. 6a, b) or by blocking P2X1 
receptors, PLD2 or PLA2 (Fig. 6c-e, h-i), indicating that a completely different signalling 
pathway, independent of astrocyte [Ca2+]i changes, mediates arteriole dilation. However, 
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again unlike the capillary dilation (Figs. 1h, 4l), arteriole dilation was strongly inhibited by 
blocking NMDA receptors (p=0.008, Fig 6 f, j) or NO synthase (p=10-6, Fig. 6g, k).  
Neurovascular signalling in vivo   
To determine whether the ATP-dependent astrocyte signalling mechanism also 
mediates neurovascular coupling at the capillary level in vivo, we used 2-photon excitation 
fluorescence microscopy to image cortical capillaries and arterioles in vivo in anesthetised 
rats, with intravascular FITC-dextran to visualise the blood vessels (Fig. 7a-b, see Methods). 
We evoked neuronal activity in the somatosensory cortex by electrically stimulating the 
forepaw. The diameter of all imaged capillaries was 6.7±0.2 m (n=102) and of arterioles 
was 13.4±0.5 µm (n=77). Forepaw stimulation evoked a dilation in 22% of capillaries and 
24% of arterioles (Fig. 7c-e). In those vessels, capillary dilation averaged 29.3±5.8% and 
arteriole dilation averaged 10.9±2.2% (Fig. 7f).  
Local infusion of the P2X1 blocker NF449 (5 M) into the cortical region did not 
significantly affect the percentage of capillaries dilating (reduced to 13%, p=0.3, Fig. 7e). 
However, the capillary dilations that did occur were reduced by 68% in size to 9.5±1.8% 
(p=0.006, Fig. 7d, f). In contrast, NF449 did not significantly alter either the percentage of 
dilating arterioles (18%, p=0.6) or the magnitude of the arteriole dilations (9.7±1.7%, p=0.7; 
Fig. 7c, e-f), just as in slices (Fig. 6h).  
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Discussion 
Neurovascular coupling plays a crucial role in controlling cerebral blood flow, both 
physiologically and in disease. Capillary dilation generates a large portion of the blood flow 
increase evoked by neuronal activity, and thus is expected to contribute significantly to the 
BOLD signal6. In ischemia, pericytes constrict capillaries, contributing to the lack of 
reperfusion of the microvasculature that occurs after a thrombus is removed from an 
upstream artery6,36. Consequently, characterising the signalling mechanisms that regulate 
capillary and arteriole dilation is important for understanding the blood flow response to 
physiological activity and to disease. In this study, we have demonstrated that neurovascular 
coupling at the capillary and arteriole levels differ mechanistically (Supp. Fig. 1). 
Neurovascular coupling at the capillary level is largely dependent on astrocyte Ca2+ 
signalling, and our data reveal a new mechanism by which astrocytes alter their [Ca2+]i in 
response to neuronal activity: influx of Ca2+ via the ionotropic ATP receptor P2X1. Thus 
astrocyte [Ca2+]i can be raised without a need for mGluR5
37 and IP3R2 mediated signalling, 
which have recently been suggested to be unnecessary for neurovascular coupling in adult 
animals15,16,38, and astrocyte Ca2+ transients observed in IP3R2 knockout mice
39 may partly 
reflect activation of P2X1 receptors. Our data are consistent with work showing that 
overexpression of an ecto-nucleotidase (to promote rapid ATP degradation) strongly reduces 
BOLD fMRI signals triggered by somatosensory stimulation in rats40. We also show that, 
although signalling to capillaries is mediated by AA metabolites, the synthesis of AA 
depends not upon PLA2 as generally assumed
2,8, but rather on PLD2 and DAGL activity. 
Furthermore, neuronal activity induced capillary dilation is unaffected by block of NO 
synthase (thus differing from the pericyte-mediated dilation we previously characterised in 
cerebellum6, presumably because of the difference in brain region (as the cerebellum 
expresses more NOS) and/or because dilation was evoked by glutamate superfusion in the 
latter study but by endogenous glutamate release here). In contrast, neurovascular signalling 
to cortical arterioles is not mediated by P2X1, astrocyte Ca
2+, PLD2 or PLA2 but, unlike 
cortical capillary dilation, requires the activation of NMDA receptors and production of NO.   
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Our data suggest that neuronal activity results in postsynaptic neurons (Fig. 1) 
releasing ATP, which acts on astrocyte ATP receptors containing P2X1 subunits to produce 
a [Ca2+]i rise (Figs. 2 and 3). This activates PLD2 (Figs. 5 and Supp. Fig. 8), resulting in AA 
synthesis via DAGL, and downstream metabolism by COX1 into vasodilatory PGE2, which is 
released onto capillary pericytes to induce dilation via the EP4 receptor (Fig. 4, Supp. Fig. 5). 
P2X1 receptors are expressed in cortical astrocytes along with P2X5 receptors
19, which can 
together form heterotrimers and contribute to Ca2+ influx. The astrocyte Ca2+ influx causing 
capillary dilation (Figs. 2, 3, 7, Supp. Fig. 4) may be via P2X1 homotrimers or P2X1/5 
heterotrimers19, as both are blocked by NF449 and activated by α,β-methylene ATP (puffed 
onto the neuropil; Fig. 2h, m and Supp. Fig. 10). Although it was previously reported that 
ATP is released40 from presynaptic terminals41, we show that NBQX blocks the capillary 
dilation, implying that postsynaptic glutamate receptor activation is needed for ATP release, 
at least in the cortex. The mechanism of this ATP release has yet to be investigated.  
In contrast to capillary dilation, arteriole dilation does not depend on P2X1 receptors, 
PLA2, PLD2 or astrocyte calcium signalling, but is dependent on NMDA receptor activation 
and nitric oxide synthesis (Fig. 6-7) as previously suggested30,31. It has been suggested that 
activation of NMDA receptors, by Ca2+-dependent release of D-serine from astrocytes, 
generates NO from eNOS in endothelial cells, and thus helps to dilate penetrating 
arterioles31. Our data showing that buffering astrocyte [Ca2+]i does not inhibit arteriole dilation 
(Fig. 6a, b) argue against a role for astrocyte Ca2+ in triggering arteriole dilation in our 
experiments, and furthermore transcriptome data suggest there are no NMDA receptors on 
endothelial cells42. We therefore assume that the NO is generated by neuronal NOS, which 
is Ca2+-dependent and predominantly located in interneurons in the cortex43,44.  
It has previously been suggested that, in the cortex, NO release is needed to maintain 
neurovascular coupling but not to mediate it45. This is similar to the idea that, in cortex31 and 
in cerebellum6, NO serves to suppress the generation of the vasoconstrictor 20-HETE from 
AA while another AA derivative, PGE2, dilates the arterioles. We have shown that blocking 
AA production by inhibiting PLA2 or PLD2 has no effect on the arteriole dilation evoked by 
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neuronal activity (Fig. 6d, e, i), leading us to favour the idea that NO may directly mediate 
arteriole dilation in our preparation. However, we cannot rule out the possibility that AA is 
generated by PLC and DAG lipase, and that downstream generation of PGE2 (or EETs, see 
below) dilates the arterioles provided that NO suppresses 20-HETE formation. 
The lack of dependence of arteriole dilation on astrocyte [Ca2+]i changes contrasts with 
earlier work1,2 in which mGluR agonists or Ca2+-uncaging evoked arteriole dilation by raising 
astrocyte [Ca2+]i. We assume this relates to the different kinds of stimuli applied: release of 
endogenous neurotransmitter glutamate from synapses in this paper, versus the generation 
of a more spatially extensive [Ca2+]i rise by bath superfusion of an mGluR agonist or 
essentially simultaneous Ca2+-uncaging in several astrocytes. Consequently we cannot 
exclude the possibility that with other stimulation paradigms (or in other brain regions) 
mGluR-driven astrocyte Ca2+ signalling may contribute to arteriole dilation, although this 
mechanism may decrease in importance with age15. 
Overall, our data indicate that two cellularly- and chemically-distinct Ca2+-dependent 
pathways mediate neurovascular coupling in response to neuronal activity evoked glutamate 
release (Supp. Fig. 1): ATP-evoked signalling in astrocytes generates PGE2 which dilates 
capillaries via pericytes, and glutamate-evoked NO release from interneurons dilates 
arterioles. Previous data6 suggest that the astrocyte-capillary pathway is faster, and 
quantitatively more important for increasing blood flow, than the interneuron-arteriole 
pathway, so our current data imply that purinergic signalling contributes significantly to 
generating BOLD signals. 
We observed a similar block of capillary dilation after astrocyte Ca2+ buffering (64% 
reduction: Fig. 2c) and inhibition of P2X1 receptors (58% reduction: Fig. 2l). The incomplete 
nature of this block (compared to that produced by inhibiting PLD2: Fig. 5k) may reflect an 
insufficient concentration of BAPTA or NF449 being applied. Alternatively, another 
mechanism might generate the remaining fraction of the response. We have ruled out direct 
signalling from neurons to pericytes via NMDA receptor mediated NO release30 (Fig. 1e, h 
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and 4i, l), but other signals or Ca2+-independent (e.g. cyclic nucleotide) mechanisms in 
astrocytes could be involved. 
Previous reports have suggested that astrocyte-mediated neurovascular signalling 
involves AA metabolites, and our data demonstrate that this is true for signalling to 
capillaries. Conceivably EETs may contribute to neurovascular signalling to arterioles under 
some conditions9,46,47, as we detected epoxygenase expression in astrocyte endfeet along 
larger vessels (but not in endfeet along capillaries (Supp. Fig. 5c) and EETs do not 
contribute to capillary dilation (Fig. 4c, f)6). Although AA production has been attributed to 
the activity of Ca2+-dependent48 PLA2
2,8, which is expressed in astrocytes33 (Supp. Fig. 6), 
we found that PLA2 is not involved in neurovascular coupling. Instead, another Ca
2+-
dependent phospholipase, PLD2, was responsible for AA production (Fig. 5h, k; Supp. Fig. 
8c, d). In the brain, PLD1 may be expressed primarily in neurons or oligodendrocytes and 
PLD2 in astrocytes34,49. Furthermore, studies of the two PLD isoforms have suggested that 
PLD1 is expressed in endosomal compartments, depending on Ca2+ release from internal 
stores for activation, whereas PLD2 tends to be membrane associated and is activated by 
Ca2+ entry through ion channels34,35. Our findings suggest that astrocytic PLD2 is activated 
by Ca2+ entry through P2X1 channels, which fits neatly with these data.  
In conclusion, neuronal activity results in capillary dilation in a manner that is largely 
dependent on Ca2+-dependent signalling in astrocytes. The astrocyte [Ca2+]i rise causing 
dilation depends on ionotropic P2X1 receptor activation, but not on GPCRs or TRPA1 
channels. AA synthesis via a PLD2-DAGL pathway, and downstream metabolism into 
prostaglandin E2 by COX1, are necessary for capillary dilation, with the required synthetic 
enzymes being expressed in astrocytes. In contrast, neuronally-evoked arteriole dilation 
depends at least partly on the activation of neuronal NMDA receptors and subsequent 
synthesis and release of NO. These data demonstrate that astrocytes are important 
contributors to neurovascular coupling at the capillary level and suggest that capillaries, 
which contain most of the resistance to blood flow in the brain parenchyma50, could be 
specifically targeted therapeutically to increase blood flow in pathological conditions. 
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Methods 
Animals. Sprague-Dawley rats of both sexes were used in all experiments. Animal 
procedures were carried out in accordance with the guidelines of the UK Animals (Scientific 
Procedures) Act 1986 and European Directive 2010/63/EU. Each experiment was conducted 
on brain slices from at least three animals (at least one of each sex). 
Brain slice preparation. As described previously22, 300 m thick coronal cortical slices 
were prepared from P21 rats on a vibratome in ice-cold oxygenated (95% O2, 5% CO2) 
solution containing (in mM) 93 N-methyl-D-glucamine chloride, 2.5 KCl, 30 NaHCO3, 10 
MgCl2, 1.2 NaH2PO4, 25 glucose, 0.5 CaCl2, 20 HEPES, 5 Na ascorbate, 3 Na pyruvate and 
1 kynurenic acid. The slices were incubated at 34°C in the same solution for 15-20 min, then 
transferred to a similar solution with the NMDG-Cl, MgCl2 and CaCl2 replaced by (mM) 93 
NaCl, 1 MgCl2 and 2 CaCl2, and incubated at room temperature (21–23°C) until used in 
experiments. 
Imaging of capillaries in brain slices. Slices were perfused with bicarbonate buffered 
aCSF containing (in mM) 124 NaCl, 2.5 KCl, 26 NaHCO3, 1 MgCl2, 2 CaCl2, 1 NaH2PO4, 10 
glucose, 1 Na-ascorbate heated to 31-35°C and gassed with 20% O2, 5% CO2 and 75% N2. 
Capillaries were imaged using differential interference contrast (DIC) microsopy at 20-50 μm 
depth within layers III-VI of cortical slices containing the motor and prefrontal cortices, using 
a 40x water immersion objective, a Coolsnap HQ2 CCD camera, and ImagePro Plus 
acquisition software. Images were acquired every 5 s, with an exposure time of 100 ms. The 
pixel size was 160 nm. The thromboxane A2 analogue U46619 (200 nM) was used to 
preconstrict capillaries in all experiments where the vessel response to stimulation was 
evaluated. Although the cerebral cortex is highly vascularized, the slicing procedure leaves 
many vessels unhealthy and unable to actively respond to stimuli22. We only analyzed 
vessels that preconstricted to U46619, in order to ensure that the vessels used in our 
experiments were healthy and responsive. Vessel internal diameters were measured by 
manually placing a measurement line perpendicular to the vessel (Fig. 1a) on the image at 
locations where constriction to U46619 occurred (presumed regions of active pericyte 
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control) using Metamorph software. Change in diameter was quantified as a 30 s average 
centred around the largest response seen after stimulation, normalized to the baseline 
diameter. Experiments in which changes in focus occurred were excluded from further 
analysis. Data in the presence of blockers of signalling pathways were compared with 
interleaved control data obtained without the blockers to avoid confounds due to day-to-day 
variability in stimulation-evoked capillary responses. Control and drug experiments were 
randomly interleaved. To reduce experimenter bias, experiments were conducted and 
analyzed blind when possible (i.e. all experiments except when the drug was colored, e.g. 
NBQX).  
Stimulation protocol for brain slices. High frequency (100 Hz) trains of short duration (200 
ms [30-90 volt, 0.2 ms]), medium duration (the short stimulation repeated once per sec for 5 
sec) or long duration (the short stimulation repeated once per sec for 1 minute) were applied 
using an aCSF-filled patch-pipette electrode placed 400-500 µm away from the imaged 
vessel. All stimulation durations evoked a capillary dilation with the same pharmacology 
(blocked by NF449: see Suppl. Fig. 3). All arteriole experiments were conducted using the 5 
s medium duration stimulation. To confirm activation of the neurons, the field potential was 
monitored near the capillary of interest using a 4 M patch pipette filled with aCSF (Supp. 
Fig. 2a, b), and only experiments where a field potential was detected were used for 
analysis. When characterizing field potentials in detail (Supp. Fig. 2), a 25 s long 12 Hz 
stimulation was used and the peak EPSC amplitude between 5 and 9 ms after stimulation 
was measured.  
Pharmacology in brain slices. For all experiments, except those using L-161,982 and 
PPOH, vessels were preconstricted with U46619 which acts on thromboxane A2 receptors 
(unpublished data kindly provided by Ben Barres, similar to those at 
http://web.stanford.edu/group/barres_lab/brain_rnaseq.html, show that pericytes express this 
receptor). The drug of interest was then bath applied for at least 5 minutes before 
stimulation-evoked capillary responses were evaluated. For L-161,982 experiments, slices 
were treated with L-161,982 for 5 minutes before preconstriction was achieved with U46619 
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(applied for 5 min) and stimulation-evoked dilations were then evaluated. This allowed us to 
confirm that PGE2 signalling via EP4 does not contribute to baseline capillary tone 
(constricted by 3.3±3.0%; p=0.3). Slices were incubated in PPOH for at least 1 hour before 
experiments and PPOH was included in all solutions (control and U46619-containing aCSF) 
to ensure that epoxygenase activity was blocked during stimulation experiments. A list of the 
drugs used is given in Supp. Table 1, along with the concentration and timeframe on which 
they have previously been shown to act.  
α,β-methylene ATP puff experiments. A 5 s puff of external solution containing α,β-
methylene ATP (100 µM) was used to activate P2X1 receptors. ATP can constrict retinal 
pericytes and arterioles directly5,51 and here we found the same effect when α,β-methylene 
ATP was bath applied to cortical slices (8.4±2.7% constriction, n=5). To avoid these direct 
effects of α,β-meATP on the vessel, the puff pipette was positioned 100-150 μm 
downstream (with respect to the perfusion flow) from the capillary of interest, with the aim of 
activating astrocytes at that location which would then signal to the imaged vessel. Lack of 
spread of the puffed solution to the imaged vessel was confirmed by including a dye in the 
puffing pipette on some occasions (Supp. Fig. 10). 
Whole-cell patch-clamping of astrocytes. Slices were superfused with bicarbonate-
buffered solution as described above, bubbled with 20% O2, 5% CO2 and 75% N2, and 
heated to 33-36°C. Astrocytes were identified as cells with a soma of small diameter (~10 
μm) that was not perfectly round. In some cases, slices were incubated at a very low 
concentration of Rhod-2 AM (4 μM), which loads relatively selectively into astrocytes and 
NG2-positive oligodendrocyte precursor cells. Astrocytes were whole-cell clamped at -80 mV 
with 3-5 M patch pipettes with different internal solutions depending on the experiment 
being carried out. The control internal solution contained (in mM) 125 K-gluconate, 2 NaCl, 
0.1 CaCl2, 10 HEPES, 1 K4-EGTA, 2 MgCl2, 2 Na2ATP, 0.5 Na2GTP, 10 Na2-
phosphocreatine and 0.04 Alexa Fluor 488, with pH set to 7.1 using KOH. The internal 
solution containing BAPTA (tetra-potassium salt) was similar but with the CaCl2 and EGTA 
replaced with (in mM) 3 CaCl2 and 30 BAPTA (so that the free [Ca
2+]i was ~24.5 nM in both 
25 
the control and the BAPTA internal solutions, calculated using MaxChelator, Stanford) and 
with osmolarity differences compensated by lowering the K-gluconate concentration. 
Osmolarity measurements showed that K4-BAPTA does not dissociate completely so that 
correspondingly less compensation of osmolarity was needed. The solution contained (mM) 
67 K-gluconate, 2 NaCl, 3 CaCl2, 10 HEPES, 30 K4-BAPTA, 2 MgCl2, 2 Na2ATP, 0.5 
Na2GTP, 10 Na2 phosphocreatine and 0.04 Alexa Fluor 488, with pH set to 7.1 using KOH.  
Patch-clamped cells were confirmed to be astrocytes morphologically by their arborization 
pattern revealed by dye filling and electrically by their large negative resting membrane 
potential (-91.6±0.6 mV, n=33), low input resistance (4.6±0.6 M) and passive I-V 
relationship.  
Calcium imaging of astrocytes. All neuronally-evoked astrocyte [Ca2+]i imaging was 
carried out by confocal microscopy using a Zeiss LSM700 microscope. The internal solution 
used for Ca2+ imaging was similar to the control internal, but with added 50 μM Fluo-4 to 
sense Ca2+ and 40 μM Alexa 594 as a reference dye to allow ratiometric imaging, and CaCl2 
increased to 0.105 mM. The intensities of Fluo4 and Alexa 594 were measured using 
GECIquant39 in a region of interest (ROI), and a background intensity measured far from the 
filled astrocyte at each time point was subtracted from the value in the ROI at the same time 
point. Data were quantified as fractional changes in the ratio of background-subtracted Fluo4 
fluorescence to Alexa 594 fluorescence. Images were acquired at 0.4 Hz. 
Immunohistochemistry. 200 μm thick coronal cortical slices were incubated in aCSF 
bubbled with 95% O2 and 5% CO2 containing 1 µM isolectin B4 conjugated to Alexa 488 
(which binds to α-D-galactose residues in the vascular basement membrane52) for 30 
minutes to label vessels, then washed with aCSF and fixed in 4% paraformaldehyde for 1 
hour. Slices were then washed 3 times in phosphate-buffered saline (PBS) and incubated in 
a blocking solution (comprised of 0.05% Triton X-100, 10% horse serum and 1% bovine 
serum albumin prepared in PBS for 1 hr) at room temperature. Slices were incubated with 
the primary antibody for 48-72 hrs at 4°C with agitation, washed 3 times with PBS, incubated 
with the secondary antibody overnight at 4°C with agitation and washed again 3 times with 
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PBS. The primary and secondary antibody solutions were prepared in PBS containing 
0.005% Triton X-100, 1% horse serum and 0.1% bovine serum albumin. Controls to test for 
non-specific labeling of the secondary antibody were carried out in exactly the same manner, 
except that slices were incubated in just the vehicle (PBS containing 0.005% Triton X-100, 
1% horse serum and 0.1% bovine serum albumin) during the primary antibody incubation 
step. The slices were then mounted with VectaShield hard set mounting medium containing 
DAPI to label nuclei. Immunohistochemistry experiments were conducted on three separate 
occasions on tissue from three different animals. Primary antibodies used were: chicken 
GFAP (Abcam, ab4674, 1:1000), rabbit AQP4 (Santa Cruz, sc-20812, 1:500) or goat AQP4 
(Santa Cruz, sc-9888, 1:500), goat COX1 (Abcam, ab22720, 1:1000), goat COX2 (Abcam, 
ab23672, 1:1000), goat PGES (Santa Cruz, sc-12268, 1:500), rabbit PLD1 (Santa Cruz, sc-
25512, 1:300), rabbit PLD2 (Santa Cruz, sc-25513, 1:200), mouse PLA2 (Santa Cruz, sc-
454, 1:300) and rabbit CYP2C11 (Abcam, ab3571, 1:300). Secondary antibodies used were: 
donkey anti-chicken Alexa 644 (Molecular Probes, 1:1000), donkey anti-chicken Cy5 
(Jackson Laboratories, 1:1000), donkey anti-rabbit Alexa 647 (Molecular probes, 1:1000), 
donkey anti-goat Alexa 568 (Molecular probes, 1:1000), donkey anti-rabbit Alexa 555 
(Molecular Probes, 1:1000) and donkey anti-mouse Cy3 (Jackson Immunoresearch 
Laboratories, 1:500). Immunolabelled slices were imaged using a Zeiss LSM700 confocal 
microscope. 
In vivo experiments: preparation. Experiments were conducted in male Sprague-Dawley 
rats (4 to 6 weeks of age). Animals were initially anaesthetised using isoflurane (5% 
induction, 2% maintenance). The femoral artery was cannulated for continuous blood 
pressure recording, as well as periodic blood gas monitoring. Following cannulation, a 
mixture of urethane (a single dose of 0.75 g/kg) and alpha-chloralose (an initial dose of 50 
mg/kg supplemented with 10 mg/kg/hr) was administered intravenously while discontinuing 
isoflurane. Adequate anaesthesia was ensured by maintaining a stable arterial blood 
pressure and the absence of a withdrawal response to a paw pinch. The trachea was 
cannulated and the animal was mechanically ventilated during imaging sessions (1:2 
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oxygen/nitrogen ratio at 80 strokes min-1 and a tidal volume of 1 ml/100 g body weight). 
Body temperature was maintained at 37.0+0.5°C. The PO2, PCO2, and pH of the arterial 
blood were periodically measured using a RAPIDLab 348EX blood gas analyzer (Siemens), 
and the ventilation parameters were adjusted to keep these variables within their 
physiological ranges (PO2 >80 mm Hg; PCO2 30-45 mm Hg; and pH 7.35-7.45). Mean 
arterial blood pressure was stable at 90-110 mm Hg throughout the experiment. The animal 
was secured in a stereotaxic frame and a craniotomy of approximately 4 mm diameter was 
carried out over the right primary somatosensory cortex, immediately caudal to the coronal 
suture and approximately 2-6 mm laterally from the midline. A durectomy was subsequently 
performed. One microliter of the P2X1 antagonist NF449 (5 μM) in artificial cerebrospinal 
fluid (aCSF; 124 mM NaCl, 3 mM KCl, 2 mM CaCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4, 1 
mM MgSO4, 10 mM D-glucose saturated with 95% O2/5% CO2 [pH 7.4]), or one microliter of 
aCSF as a vehicle control, was pressure injected at 3-4 sites throughout the exposed cortical 
area, at a depth of 500 μm, using a glass micropipette. In order to distinguish cortical 
arterioles from venules and capillaries, Alexa 633 hydrazide53 (35 μM, 1 μl) was included in 
the injection bolus. The cortical surface was covered with 0.8% agarose and a glass 
coverslip was placed on top. A custom built headplate was then attached to the skull and the 
entire assembly secured using dental cement. During imaging, the headplate was secured 
under the objective on a custom built stage. 
In vivo experiments: imaging. Cortical vessel diameter was recorded using 2P microscopy 
of the intraluminal dye fluorescein isothiocyanate-dextran (FITC-dextran, MW 2000 kDa, 50 
mg/kg, 1 ml i.v.). Two-photon excitation was carried out using a Newport-Spectraphysics 
Ti:Sapphire MaiTai laser pulsing at 80 MHz, and an Olympus FV1000 with XLPlan N 25x 
water immersion objective (NA 1.05). Acquisitions were carried out using a wavelength of 
800 nm and the mean laser power under the objective was kept at 20–30 mW. Penetrating 
arterioles were identified by chromatically separated Alexa 633 hydrazide fluorescent 
labelling of the smooth muscle elastin53. Recordings were made at a depth between 50 and 
250 μm from the cortical surface. XY-time series (at 1–4 Hz with a pixel dwell time of 2 μs 
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and pixel size of 0.248-0.496 μm) were taken of regions of interest to record vessel dilations 
in response to somatosensory stimulation. Unilateral forepaw stimulation (0.3 ms pulse 
width, 3 Hz, 0.2-2 mA, 20 s) was applied using an electrical stimulator triggered by a 1401 
interface (Cambridge Electronic Design).  
In vivo experiments: analysis. The presence of red blood cells (RBCs) leads to apparent 
holes in the images of the capillary and (to a lesser extent) the arteriole. This image noise 
was reduced by smoothing images in the time series with a rolling window (in time) 
maximum intensity projection not exceeding 2 s duration, as previously described6. The 
resulting time series was then median filtered (radius 1 pixel) using ImageJ. A 3-pixel wide 
line-segment was drawn perpendicular to the vessel in ImageJ and the fluorescence profile 
across the vessel was extracted. Relative diameter was determined by fitting a function to 
the fluorescence profile in Matlab (using the sum of 2 Gaussian functions), and calculating 
the full width at quarter-maximum of the peak fluorescence intensity. The peak dilation and 
the time to 10% of the peak dilation were calculated by fitting the data with a function of the 
form: (max dilation).(timen)/(timen+Kn), with max dilation, n and K arbitrary constants 
Statistics. Data are shown as box and whisker plots in which the central line shows the 
median, the central dot shows the mean, the edges of the box define the upper and lower 
quartile values, and the outer whiskers show the minimum-maximum range of the data, or 
are shown as mean±s.e.m. N numbers on bars are of capillary regions or arterioles. The 
variability of responses observed at different regions (presumed regions of active pericyte 
control) along the same capillary was higher than that between different capillaries, slices or 
animals. Therefore, capillary regions that constricted to 200 nM U46619 were used as the 
observational units. Normality of data was verified using the Kolmogorov-Smirnoff test and 
the equality of variance confirmed using the F-statistic. All data were compared to 
interleaved controls using a homoscedastic, two-sided Student’s t-test (equal variance), 
except in Figs. 3c, 4j, 7f and Supp. Fig. 4d, where the variances of the data were unequal, 
and therefore a heteroscedastic, two-sided Student’s t-test was used. Data in Supp. Fig. 2 
were compared using a one-way ANOVA and corrected for multiple comparisons using a 
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procedure equivalent to the Holm-Bonferroni method (for N comparisons, the most 
significant p value is multiplied by N, the 2nd most significant by N-1, the 3rd most significant 
by N-2, etc.; corrected p values are significant if they are less than 0.05). An estimate of the 
sample size needed for a typical experiment is as follows: For a control response of 100%, a 
typical response standard deviation of 40%, a response in a drug of 30% (70% inhibition), a 
power of 80% and p<0.05, 7 vessels are needed (http://www.biomath.info/power/ttest.htm) in 
each of the control and drug groups. The exact numbers depend on the drug effect size and 
standard error of the data. 
Materials. TTX, NBQX, D-AP5, S-MCPG, MRS2179 and A967079 were obtained from 
Tocris Biosciences; U46619, NF449, L-161982, U73122, CAY10441, PPOH, MAFP and FIPI 
from Cayman Chemicals; NS-398 and SC-560 from Calbiochem-Merck Millipore; RHC-
80267 from Enzo Life Science; VU0155069 and CAY10594 from Santa Cruz; L-NNA, α,β-
methylene ATP, NF023 and PGE2 from Sigma; Alexa Fluor 488, Alexa Fluor 594, Fluo-4 
pentapotassium salt, BAPTA tetrapotassium salt and Alexa Fluor 488 or FITC conjugated 
IB4 from Life Technologies; and PBS and Alexa Fluor 633 hydrazide from Thermo Scientific. 
All other salts and reagents were purchased from Sigma.  
 
Data Availability 
The data that support the findings of this study are available from the corresponding author 
upon request. 
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Figure Legends 
Figure 1. Neuronal activity evokes capillary dilation. (a) A cortical capillary response to 
200 nM U46619 and superimposed neuronal stimulation (stim). Lines show lumen diameters 
plotted in b. (b) U46619 evoked constriction and stimulation-evoked dilation at regions 
indicated in a (in this and subsequent example traces, a large response is shown for 
illustrative purposes). (c) 500 nM TTX blocks stimulation-evoked capillary dilation. (d) 10 µM 
NBQX blocks stimulation-evoked dilation. (e) 25 µM D-AP5 did not reduce stimulation-
evoked dilation. (f-h) Mean data showing the block of capillary dilation by TTX (f) and NBQX 
(g) but not by D-AP5 (h). Numbers on bars are capillary regions (putative pericytes) studied. 
Data are shown as box and whisker plots as defined in the Statistics part of the Methods. 
Figure 2. P2X1-evoked astrocyte Ca
2+ signalling mediates capillary-level neurovascular 
coupling. (a) A DIC image of a cortical capillary (left panel) and the AlexaFluor 488 fill of the 
astrocyte network after whole-cell patch-clamp dialysis for 1 min (middle) and 10 mins (right) 
after breaking into the cell. Whole-cell patch-clamped cell is indicated by arrowhead and 
endfoot indicated by arrow. (b) Example traces and (c) mean data demonstrating that 
stimulation-evoked capillary dilation is intact when the astrocyte network is dialyzed with a 
control internal solution containing 1 mM EGTA but significantly reduced when filled with 30 
mM BAPTA, a fast Ca2+-chelator. (d-f) An inhibitor of group I and II mGluRs, S-MCPG (1 
mM; d), the P2Y1 blocker MRS2179 (25 μM; e) and the TRPA1 blocker A967079 (10 μM; f) 
do not block stimulation-evoked capillary dilation. (g) The P2X1 blocker NF449 (100 nM) 
significantly reduced stimulation-evoked capillary dilation. (h) Puff-application of the P2X1 
agonist ,β-methylene ATP (,β-meATP, 100 µM) to the neuropil downstream of the vessel 
induces capillary dilation. (i-l) Quantification of the effect of S-MCPG (i), MRS2179 (j), 
A967079 (k) and NF449 (l) on capillary dilation. (m) Mean response of capillaries in 
experiments like those in h, puffing external solution (control) or ,β-methylene ATP. 
Change in diameter in control experiments was measured as a 30 s average centred around 
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the largest response seen between 30 and 120 s after puff of ,β-methylene ATP. Data are 
shown as box and whisker plots as defined in the Statistics part of the Methods. 
Figure 3. Neuronally-evoked astrocyte [Ca2+]i rise depends on P2X1 receptors. (a) An 
astrocyte patch-loaded with AlexaFluor 594 (top) and Fluo4 (bottom) showing the processes, 
endfoot and soma. White dashed lines delineate the vessel lumen ensheathed by the 
endfoot process. (b) Neuronal stimulation evoked a [Ca2+]i rise in astrocyte endfeet in control 
conditions (left); the rise was smaller in the presence of the P2X1 blocker NF449 (100 nM, 
right). Arrow indicates a spontaneous Ca2+ transient, demonstrating that Fluo-4 could still 
detect [Ca2+]i transients with NF449 present. (c) Mean change in neuronally-evoked 
astrocyte [Ca2+]i in somata, processes and endfeet in the absence and presence of different 
blockers. NF449 (black bars), a blocker of P2X1 channels, significantly reduced the [Ca2+] 
rise in processes and endfeet, but S-MCPG, a blocker of groups I and II mGluRs had no 
effect on astrocyte [Ca2+] in any compartment (grey bars). Time to 10% of the peak and to 
the peak [Ca2+] change in endfeet were 5.27+1.15 s and 11.57+2.39 s respectively. Data are 
shown as box and whisker plots as defined in the Statistics part of the Methods. 
Figure 4. AA metabolites mediating stimulation-evoked capillary dilation. (a) The 
COX1 blocker SC-560 (1 μM) blocks the dilation. (b,c) The COX2 blocker NS-398 (10 μM; 
b) and the epoxygenase inhibitor PPOH (25 μM; c) had no effect on the dilation. (d-f) Mean 
data for the effect of SC-560 (d), NS-398 (e) and PPOH (f) on capillary dilation. (g) Blocking 
the PGE2 receptor EP4
 with L-161,982 (1 μM) inhibits dilation. (h,i) Blocking the PGI2 
receptor IP with CAY10441 (1 μM; h) or NO synthase with L-NNA (100 μM; i) has no effect 
on capillary dilation. (j-l) Mean data showing that capillary dilation is blocked by L-161,982 
(j), but not by CAY10441 (k) or L-NNA (l). Data are shown as box and whisker plots as 
defined in the Statistics part of the Methods. 
Figure 5. PLD2, not PLA2, initiates neurovascular coupling at the capillary level. (a) 
The PLA2 inhibitor MAFP (10 μM) does not block stimulation-evoked capillary dilation. (b) 
The PLC blocker, U73122 (10 μM), does not reduce dilation. (c) The PLD blocker FIPI (1 
μM) inhibits dilation. (d-f) Mean data showing the effects of MAFP (d), U73122 (e) and FIPI 
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(f) on capillary dilation. (g) Blocking PLD1 with VU0155069 (500 nM) had no effect on the 
dilation. (h-i) The PLD2 blocker CAY10594 (1 μM; h) and the DAGL blocker RHC80267 (50 
μM; i) significantly reduce the capillary dilation. (j-l) Mean data showing the effect of 
VU0155069 (j), CAY10594 (k) and RHC80267 (l) on capillary dilation. Data are shown as 
box and whisker plots as defined in the Statistics part of the Methods. 
Figure 6. Neurovascular signalling to arterioles is mediated by NMDAR and NOS 
activity, and not by astrocyte Ca2+. (a) Example traces and (b) mean data demonstrating 
that stimulation-evoked arteriole dilation is not altered when the astrocyte network is dialyzed 
with 30 mM BAPTA, a fast Ca2+-chelator, compared to a control internal solution containing 1 
mM EGTA. (c-e) The P2X1 blocker NF449 (100 nM; c), the PLA2 inhibitor MAFP (10 μM; d) 
and the PLD2 blocker CAY10594 (1 μM; e) do not block stimulation-evoked arteriole dilation. 
(f-g) The NMDA receptor blocker D-AP5 (25 μM; f) and the NO synthase blocker L-NNA 
(100 μM; g) abolished the arteriole dilation. Mean data showing the effect of NF449 (h), 
MAFP (i), CAY10594 (i), D-AP5 (j) and L-NNA (k) on arteriole dilation. Data are shown as 
box and whisker plots as defined in the Statistics part of the Methods. 
Figure 7. Neurovascular signalling to capillaries in vivo is mediated by P2X1 
receptors. (a) Two-photon stack (90 µm thick, maximum intensity projection) of FITC-
dextran-filled vessels (green) in the somatosensory cortex of an anaesthetised rat. (b) 
Enlarged image showing a penetrating arteriole with a capillary branching off it. (c-d) 
Example traces of forepaw stimulation-evoked dilation of arterioles (c) and capillaries (d) in 
the presence of vehicle (aCSF, black traces) or the P2X1 blocker NF449 (5 μM; red traces). 
Capillary dilations occurred faster than arteriole dilations (time to 10% dilation was 3.0±0.8s 
for 12 capillaries and 5.1±1.7s for 9 arterioles), as previously reported6; however, reflecting 
the smaller number of vessels studied, this effect did not reach significance in this study 
(p=0.3). (e) The percentage of arterioles (Art) and capillaries (Cap) that dilated in response 
to stimulation was not significantly different in NF449 and vehicle-treated animals. (f) 
Forepaw stimulation-evoked mean arteriolar dilation was similar in vehicle and NF449 
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treated animals, but capillary dilation was significantly inhibited by NF449. Data are shown 
as box and whisker plots as defined in the Statistics part of the Methods. 
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Supplementary Figure Legends 
Supplementary Figure 1. Schematic diagram of the mechanisms underlying 
neurovascular signalling to capillaries and arterioles. Synaptic activity (top) evokes ATP 
release from post-synaptic neurons, which activates ionotropic ATP receptors containing 
P2X1 subunits on astrocytes, leading to a rise in [Ca
2+]i via influx from the extracellular 
space. This rise in [Ca2+]i activates PLD2, resulting in the formation of phosphatidic acid (PA) 
which is converted into diacylglycerol (DAG), which is then further metabolized by DAG 
lipase into arachidonic acid (AA). AA is then metabolized, by the consecutive activity of 
COX1 and PGES, to produce PGE2, which dilates capillaries by acting on EP4 receptors, 
presumably on pericytes. Synaptic activation of Ca2+ entry through NMDA receptors 
increases NOS activity in interneurons, resulting in NO release onto arterioles to dilate them. 
The neurovascular coupling pathways involved in signalling to capillaries and arterioles are 
highlighted in blue, while the enzymes and receptors ruled out by our experiments are 
shown in red with black crosses. 
Supplementary Figure 2. Stimulation-evoked field potentials and identification of 
vessels. (a-b) A schematic (a) and a low-magnification image (b) of a cortical slice 
demonstrating the placement of the stimulation and recording electrodes. Cortical layers are 
indicated. Inset shows a high magnification image of the recording electrode near a capillary. 
(c) Stimulation-evoked fibre volley and field excitatory post-synaptic currents (fEPSCs) are 
not affected by U46619. NBQX blocks the fEPSCs but not the fibre volley and TTX blocks 
both the fibre volley and the fEPSCs. (d) Mean data (peak fEPSC amplitude measured 5 to 
9 ms after the stimulation) showing the effect of U46619 and NBQX on fEPSCs. (e) 
Arterioles can be distinguished by the thick layer of smooth muscle cells (SMC, white 
brackets) that surround them, shown here alongside FITC-isolectin B4 (IB4) labeling of the 
basement membrane. (f, g) Capillaries are identified as smaller vessels that have only 
occasional pericyte cell bodies (arrowheads) outlined by the IB4-labeling. IB4 also labels 
microglia (asterisk). Vessel lumen is marked by red brackets. Data shown as mean±s.e.m. 
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Supplementary Figure 3. Constriction of cortical capillaries evoked by U46619 before 
each experiment. (a) Example trace of a U46619 (200 nM) induced capillary constriction 
lasting at least 30 minutes. (b-x) Mean constriction of capillaries to U46619 in interleaved 
control and drug experiments for the: (b) voltage-gated sodium channel blocker TTX, (c) 
AMPA/KA receptor blocker NBQX, (d) NMDA receptor blocker D-AP5, (e) fast Ca2+ chelator 
BAPTA, (f) inhibitor of group I and II mGluRs S-MCPG, (g) P2Y1 blocker MRS2179, (h) 
TRPA1 blocker A967079, (i) P2X1 blocker NF449, (j) P2X1 blocker NF023, (k) COX1 blocker 
SC-560, (l) COX2 blocker NS-398, (m) epoxygenase blocker PPOH, (n) EP4 receptor 
blocker L-161,982, (o) IP receptor blocker CAY10441, (p) NO synthase blocker L-NNA, (q) 
PLA2 blocker MAFP, (r) PLC blocker U73122, (s) PLD blocker FIPI, (t) PLD1 blocker 
VU0155069, (u) PLD2 blocker CAY10594, (v) DAGL blocker RHC80267, (w) P2X1 agonist 
,β-meATP, and (x) PGE2 in the presence or absence of the PLD blocker FIPI. P-values 
comparing U46619-evoked constrictions for control and drug experiments were >0.05 for all 
panels even without correcting for multiple comparisons. For experiments involving BAPTA 
(e), PPOH (m) and L-161,982 (n), U-46619 was applied in the presence of the relevant drug 
(see Methods). For all other experiments, vessels were pre-constricted with U46619 before 
drug application. Data shown as mean±s.e.m. 
Supplementary Figure 4. Signalling to capillary pericytes is similar for different 
stimulation durations in P21 rats, and in P45 rats. Mean dilation (left panels) and time 
traces of the diameter change (right panels) observed in cortical capillaries following 
electrical stimulation of neuronal activity (at 100 Hz for 0.2 sec, repeated once/sec) in the 
absence and presence of P2X1 blockers. (a-c) Capillary dilation evoked by short (200 ms; a), 
medium (5 sec; b) or long duration (1 min; c, reproduced from Fig. 2l) stimulation in slices 
from P21 rats is inhibited by the P2X1 blocker NF449 (100 nM). (d) Stimulation-evoked 
capillary dilation in slices from P21 rats is inhibited by a second P2X1 blocker NF023 (5 µM). 
(e) Stimulation-evoked capillary dilation in slices from P45 rats is also inhibited by the P2X1 
blocker NF449 (100 nM). Data shown as mean±s.e.m. 
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Supplementary Figure 5. COX1 and PGES are expressed in astrocyte endfeet along 
vessels. (a) AQP4-expressing astrocyte endfeet along arterioles (arrows) and capillaries 
(arrowheads) are immunoreactive for COX1. Vascular basement membrane is labeled with 
Alexa dye conjugated isolectin B4 (IB4). (b) COX2 is absent from GFAP-expressing astrocyte 
somata (white asterisk) and endfeet (arrowhead) but is expressed in neuronal cell bodies 
(black asterisk). (c) Epoxygenase (CYP2C11) is expressed in AQP4-expressing astrocyte 
endfeet along arterioles (arrows) but not in those along capillaries (arrowhead). Arterioles 
can be identified as larger vessels, often with space between layers of IB4-labeled basement 
membrane (white circle) where the vascular smooth muscle cells are located. (d) PGES is 
expressed in GFAP-expressing astrocyte cell bodies (white asterisk), processes and endfeet 
along vessels (arrowheads). (e) Control experiments where slices were incubated with the 
secondary antibody used to stain the enzyme shown in the corresponding panels in a-d, but 
with the primary antibody omitted, demonstrating the lack of non-specific binding. Control for 
the secondary antibody used to detect COX1 is shown in the top row, COX2 in the second 
row, epoxygenase in third row and PGES in the fourth row. 
Supplementary Figure 6. PLA2 is expressed in GFAP-labeled astrocyte endfeet along 
the vasculature. Arrowhead indicates a pericyte cell body. 
Supplementary Figure 7. PLD is upstream of PGE2 in the signalling pathway. (a) After 
preconstriction with 200 nM U46619, applying 1 µM PGE2 evokes a dilation. (b) A similar 
PGE2-evoked dilation was seen in the presence of 1 µM FIPI to block PLD1 and PLD2. (c) 
Quantification of data from experiments like those in panels a-b, showing that PLD inhibition 
does not affect the capillary dilation evoked by PGE2. Data shown as mean±s.e.m. 
Supplementary Figure 8. PLD1 and PLD2 expression in the cortex. (a, b) PLD1 was 
diffusely expressed in the cortical neuropil and appeared concentrated in endothelial cells 
along arterioles (arrow, a) but not capillaries (b). No PLD1 labeling was observed in AQP4-
labeled endfeet (arrowheads). (c, d) PLD2 expression was detected in GFAP-expressing 
astrocyte endfeet along capillaries (arrowheads, c) as well as in astrocyte somata (asterisks, 
d). (e) Control experiments where slices were labeled with the secondary antibody used to 
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detect the enzymes shown in the corresponding panels in a-d, but with the primary antibody 
omitted, demonstrating the lack of non-specific binding. Control for secondary antibodies 
used to detect PLD1 is shown in the top two panels and for PLD2 is shown in the last two 
panels (for these pictures illumination was applied appropriate for evoking fluorescence from 
the secondary antibody used for PLD1/PLD2 labeling and from the dye-conjugated IB4 or 
DAPI). 
Supplementary Figure 9. Constriction of cortical arterioles evoked by U46619 before 
each experiment. Mean constriction of arterioles to U46619 in interleaved control and drug 
experiments for the: (a) P2X1 blocker NF449, (b) PLA2 blocker MAFP and PLD2 blocker 
CAY10594 (experiments were on the same animals with interleaved controls in common), 
(c) fast Ca2+ chelator BAPTA, (d) NMDA receptor blocker D-AP5, (e) NO synthase blocker L-
NNA. P-values comparing U46619-evoked constrictions for control and drug experiments 
were >0.05 for all panels even without correction for multiple comparisons. Data shown as 
mean±s.e.m. 
Supplementary Figure 10. Experimental set-up for puffing α,β-methylene ATP. (a) DIC 
image of slice showing a capillary. (b) DIC image of the slice surface showing position of the 
puff pipette. (c) Fluorescence image showing the pipette containing Alexa Fluor 594 
positioned above the slice. (d-i) The spread of the Alexa Fluor 594 dye imaged at the start 
(d) and 5 consecutive seconds (e-i) following a 5 s puff at 5 psi. Note how the dye flows 
downwards and does not reach the location of the vessel at the top (demarcated by white 
dotted lines).  
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Supplementary Table 1. The concentration used, IC50/Ki and timeframe of action 
reported previously for the blockers used in this study. 
Drug Blocker for 
Working 
concentration 
Selectivity  
Concentration 
used 
Shown to 
work within 
Reference 
SC-560 COX1 IC50=9 nM 
High, blocks COX2 
with IC50 of 6 µM 
1 µM 6 min 54 
NS-398 COX2 IC50=1.8 µM 
High, blocks COX1 
with IC50 of 75 µM 
10 µM 2 min 55 
PPOH 
CYP450 
Epoxygenase 
IC50=9 µM 
Highly selective 
against CYP450  
ω-hydroxylases 
25 µM 30 min 56 
L-161,982 
PGE2 
receptor EP4 
Ki= 240 nM 
Selective against 
prostaglandin 
receptors; Ki=0.7 µM 
for TxA2 receptor 
1 µM 5 min 6 
CAY10441 
(RO1138452) 
PGI2 receptor 
IP 
IC50=1.5 nM 
Selective against COX 
and EP1-4 receptors 
1 µM 2 min 57, 58 
MAFP PLA2 IC50=0.5 µM 
Does not block PLC or 
PLD 
10 µM 5 min 59 
U73122 PLC IC50= 30 nM 
Selective against 
phospholipases, may 
potentiate IP3-
mediated Ca
2+
 rise 
10 µM 3 min 60 
FIPI PLD 
IC50= 25 nM 
(PLD1), 20 nM 
(PLD2) 
Highly selective for 
PLD1 and PLD2 
1 µM 5 min 61 
VU0155069 PLD1 IC50= 46 nM IC50=0.9 µM for PLD2 500 nM 5 min 62 
CAY10594 PLD2 IC50= 10 nM IC50=1-5 µM for PLD1 1 µM 5 min 62 
RHC80267 DAG lipase IC50= 4 µM 
Selective against 
PLA2 and PLC 
50 µM 2 min 63 
NF449 
P2X1 
receptors 
IC50=0.3 nM 
(P2X1), 0.7 nM 
(P2X1/5) 
High, blocks P2X3 with 
IC50 = 1 µM 
100 nM 5 min 64 
NF023 
P2X1 
receptors 
IC50=0.24 µM  
High, blocks P2X3 with 
IC50 = 8.5 µM and 
P2X2 at >50 µM 
5 µM  Immediately 65 
 
 
 
5 min
20 % 
U46619b
Stim%
 ∆ 
in
 d
ia
m
et
er
Figure 1
a U46619+recoveryU46619+StimU46619
10 µm
c
5 min
20%
U46619
TTX
Stim%
 ∆ 
in
 d
ia
m
et
er
VGSC d
U46619
NBQX
Stim%
 ∆ 
in
 d
ia
m
et
er
5 min
20%
AMPA receptor e
U46619
D-AP5
Stim5 min
20%
%
 ∆ 
in
 d
ia
m
et
er
NMDA receptor
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
(7) (11)
f p=0.00008
-10
0
10
20
Control TTX
(11) (10)
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
h p=0.6
0
10
20
30
Control D-AP5
(7) (10)
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
g p=0.002
- 10
0
10
20
Control NBQX
DIC
Alexa 488
1 min 10 min
Figure 2
20 µm
i kj
Control MRS2179
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
Control S-MCPG
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
Control NF449
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
(8) (9)(9) (8) (11) (13)
p=0.8p=0.1    p=0.0007l p=0.3
Control A967079
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
(12) (13)
d fe g
5 min
10 % 
U46619
NF449
%
 ∆
 in
 d
ia
m
et
er
Stim5 min
10 % 
U46619
S-MCPG
%
 ∆
 in
 d
ia
m
et
er
Stim 5 min
20 % 
U46619
MRS2179
%
 ∆
 in
 d
ia
m
et
er
Stim
U46619
A967079
%
 ∆
 in
 d
ia
m
et
er
Stim5 min
10 % 
groups I+II mGluRs P2Y1 TRPA1 P2X1
Control BAPTA
p=0.001
(12) (17)
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
10 %
5 min
U46619
Control internal
Stimwhole 
cell
cell
attach
U46619
BAPTA internal
Stim
cell
attach whole 
cell
%
 ∆
 in
 d
ia
m
et
er
a b c
D
ila
tio
n 
to
 p
uf
f 
(%
 b
as
el
in
e)
p=0.0007
Control α,β-meATP
m
(10) (11)
h
α,β-meATP
5 min
20 % 
U46619
%
∆ 
in
 d
ia
m
et
er
P2X1 agonist
-30
-15
0
15
30
0
10
20
30
0
20
40
0
10
20
30
0
10
20
-10
0
10
20
30
2 min
20 %
 
C
a2
+  
(Δ
R
/R
)
a Control NF449
Figure 3
Stim Stim
c
(5) (5)(9) (8) (7) (7)(9) (6)(13) (8) (23) (14)
St
im
-e
vo
ke
d 
C
a2
+  
(Δ
R
/R
)
NF
44
9 
S-M
CP
G
 Co
ntr
ol
NF
44
9 
 Co
ntr
ol
NF
44
9 
 Co
ntr
ol
 Co
ntr
ol
S-M
CP
G
 Co
ntr
ol
S-M
CP
G
 Co
ntr
ol
EndfootSoma ProcessEndfootSoma Process
b
10 µm
AlexaFluor594
Fluo4
process
endfoot
soma
0
50
100
150
250
450 p=0.2 p=0.02 p=0.8 p=0.7p=0.02 p=0.5
Control L-161,982 Control CAY10441
Control SC-560 Control NS-398
d
a b c
e
Control PPOH
(14) (13)
(15) (12)(10)(12)(13)(11)
(8) (9)
p=0.0002 p=0.5 p=0.4
p=0.004 p=0.6
Di
la
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
Di
la
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
Di
la
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
Di
la
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
Di
la
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
f
Figure 4
5 min
20 % 
U46619
L-NNA
Stim%
 ∆
 in
 d
ia
m
et
er
Control L-NNA
Di
la
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
p=0.8
(11) (15)
g h i
j k l
5 min
10 % 
U46619
Stim
SC-560
%
 ∆
 in
 d
ia
m
et
er
5 min
10 % 
U46619
NS-398
Stim 5 min
20 % 
U46619
Stim
5 min
10 % 
L-161,982
U46619
Stim%
 ∆
 in
 d
ia
m
et
er
5 min
20 % 
U46619
CAY10441
Stim%
 ∆
 in
 d
ia
m
et
er
PPOH
%
 ∆
 in
 d
ia
m
et
er
%
 ∆
 in
 d
ia
m
et
er
EP4 IP NOS
COX1 COX2 Epoxygenase
0
10
20
30
0
10
20
30
40
0
10
20
30
0
10
20
30
40
0
10
20
30
40
50
0
10
20
30
40
Control MAFP Control FIPI
Control VU0155069 Control CAY10594 Control RHC80267
a b c
j
i
(15) (13) (7)(5)
(6) (9) (8) (11)
(8)(11)
p=0.3
p=0.6 p=0.0002
p=0.0005
p=0.0004
D
ila
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
D
ila
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
D
ila
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
D
ila
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
D
ila
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
Figure 5 
d e f
hg
Stim
5 min
20 % 
U46619
FIPI
Stim%
 ∆
 in
 d
ia
m
et
er
5 min
20 % 
%
 ∆
 in
 d
ia
m
et
er
Stim
U46619
MAFP
5 min
20 % 
U46619
%
 ∆
 in
 d
ia
m
et
er
Stim
VUO155069
5 min
10 % 
U46619
CAY10594
%
 ∆
 in
 d
ia
m
et
er
Stim 5 min
10 % 
U46619
RHC80267
%
 ∆
 in
 d
ia
m
et
er
Control U73122D
ila
tio
n 
to
 s
tim
ul
at
io
n
 (%
 b
as
el
in
e)
lk
p=0.9
5 min
10 % 
%
 ∆
 in
 d
ia
m
et
er
Stim
U46619
U73122
(11)(11)
PLA2 PLC PLD
PLD1 PLD2 DAGL
0
10
20
30
0
10
20
30
0
10
20
30
0
10
20
30
-30
-15
0
15
30
-10
0
10
20
30
5 min
5% 
Stim
whole 
cell
cell
attach
cell
attach
U46619
Control internal
U46619
BAPTA internal
1
Control BAPTA
Control MAFP CAY10594
p=0.4
p=0.5
p=0.008 p=0.000001
L-NNAControl D-AP5Control NF449
p=0.7
D
ila
tio
n 
to
 s
tim
ul
at
io
n
(%
 b
as
el
in
e)
(9) (8) D
ila
tio
n 
to
 s
tim
ul
at
io
n
(%
 b
as
el
in
e)
a
whole 
cell
Stim%
 ∆
 in
 d
ia
m
et
er
%
 ∆
 in
 d
ia
m
et
er
D
ila
tio
n 
to
 s
tim
ul
at
io
n
(%
 b
as
el
in
e)
p=0.6
(4) (4)
b
h i
PLA2 NMDA
D
ila
tio
n 
to
 s
tim
ul
at
io
n
(%
 b
as
el
in
e)
j k
D
ila
tio
n 
to
 s
tim
ul
at
io
n
(%
 b
as
el
in
e)
Control
NOS
Figure 6
(7) (8)(10) (10)(6) (6) (6)
%
 ∆
 in
 d
ia
m
et
er U46619
NF449
Stim
P2X1
5 min
5% 
c d g
U46619
D-AP5
Stim5 min
5% 
%
 ∆
 in
 d
ia
m
et
er
%
 ∆
 in
 d
ia
m
et
er
%
 ∆
 in
 d
ia
m
et
er U46619
L-NNA
Stim5 min
5% 
PLD2e f
U46619
MAFP
Stim5 min
5% 
U46619
CAY10594
Stim5 min
5% 
%
 ∆
 in
 d
ia
m
et
er
0
2
4
6
8
10
12
-10
-5
0
5
10
15
0
5
10
15
20
-10
-5
0
5
10
15
-5
0
5
10
15
0
5
10
15
20
25
10 s
20% 
Stim%
 ∆
 in
 d
iam
et
er
10 s
 %
 d
ila
tio
n
p=0.6 p=0.3
p=0.7
p=0.006
a b
c d
%
 v
es
se
ls 
re
sp
on
di
ng
Arterioles Capillaries
Art Cap
e f
Art Cap
Figure 7
Stim
Con NF Con NF Con NF Con NF
Capillary
Arteriole
9/38
7/39 6/47
12/55
(9) (7) (6) (12)
Control
NF449
5% 
50 µm 10 µm
0
20
40
60
Membrane
phospholipids
EP4
NEURONS
Pre
Post
Supplementary Figure 1
IP
Ca2+
AA
PGE2
PLD2
PA
DAG
DAG
lipase
PLC
PLD1
PGI2
Glu
M
UILE
HT
O
D
NE
PERICYTES
SLLE
C EL
CS
U
M 
HT
O
O
MS 
RAL
U
CSAV
CAPILLARY
W
OLF 
D
O
OLB
P2X1
NO
ATP
PGH2
COX2
COX1
PLA2
ASTROCYTE
PGISPGES
AMPAR
NMDAR
NOSCa2+
Control
U46619
NBQX
TTX
10 pA
5 ms
0
2
4
6
8
10
Control U46619 NBQX
p=0.00006
fE
PS
C
 (p
A)
p=0.001
9 9
9
fibre volley
stimulus 
artifact
fEPSC
a b
Supplementary Figure 2
p=0.2
II/III
IV
V
VI
Stimulating 
electrode
Corpus 
callosum
Capillary
I
Thalamic 
input
Recording 
electrode
Output
local synaptic 
input
c d
Recording 
electrode
Stim. 
electrode
II/III
IV
V
VI
I
e
f
g
*
DIC IB4 Merge
10 µm
10 µm
10 µm
Ar
te
rio
le
C
ap
illa
ry
C
ap
illa
ry
lumen
SMC
lumen
lumen
 0
 5
10
15
20
25
Control TTX
%
 co
ns
tric
tio
n 
0
5
10
15
20
25
Control NBQX
0
10
20
30
Control D-AP5
0
5
10
15
Control S-MCPG 0
5
10
15
20
Control NF449
b c
e f
0
5
10
15
20
25
Control MRS2179
g
0
5
10
15
20
Control A967079
h i
j k l m n
o p
0
5
10
15
Control SC-560
0
5
20
25
Control α,β-meATP
0
5
10
15
Control NS-398
0
5
10
15
20
Control CAY10441
0
5
10
15
20
Control L-NNA
u
0
5
10
15
20
Control RHC80267
10
15
0
5
20
25
10
15
Supplementary Figure 3
NMDA receptor
Ca2+ chelator group I & II mGluRs P2Y1 TRPA1 P2X1
P2X1 agonist 
COX1
IP receptor NOS q
0
5
10
15
20
25
30
Control MAFP
PLA2
t
0
5
10
15
20
25
Control VU0155069
PLD1
0
5
10
15
20
25
Control FIPI
30 PLD
0
5
10
15
20
25
Control CAY10594
PLD2 DAGLv w
r PLC
0
5
10
15
20
25
30
Control U73122
0
5
10
15
20
25
PGE2 PGE2+FIPI
PLD
VGSC AMPA receptor
117 107 1011
1712 89 98 1312 1311
1311 1012
1314 1511 96 1111 118
811 1315 75 1110 1819
0
5
10
15
20
25
Control PPOH
Epoxygenase
1215
0
5
10
15
20
25
Control L-161,982
EP4 receptor
98
5 min
10 % 
U46619
%
 ∆
 in
 di
am
ete
r
a
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
d
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
%
 co
ns
tric
tio
n 
0
5
10
15
Control NF023
P2X1
%
 co
ns
tric
tio
n 
Control BAPTA
COX2
s
x
69
05
10
15
Control NF449
Di
la
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
a
p=0.01
6
5
0
5
10
15
Control NF449
Control NF449
Di
la
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
Di
la
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
p=0.005
p=0.00008
13 11
7 9
e
d
b
Di
la
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
p=0.001
9
6
Control NF023
0
5
10
15
Supplementary Figure 4
200 ms stim
2nd P2X1 blocker
5 s stim
0
5
10
15
5 s stim
5 s stim
c
0
5
10
15
20
Control NF449
D
ila
tio
n 
to
 s
tim
ul
at
io
n 
(%
 b
as
el
in
e)
8 9
   p=0.0007
60 s stimP
21
P4
5
5 % 
5 s stim
1 min
%
 ∆
 in
 d
iam
et
er
5 % 
1 min
%
 ∆
 in
 d
iam
et
er
%
 ∆
 in
 d
iam
et
er
%
 ∆
 in
 d
iam
et
er
%
 ∆
 in
 d
iam
et
er
200 ms stim
5 % 
1 min
60 s stim
Control
NF449
5 % 
1 min
5 s stim
5 % 
1 min
5 s stim
Control
NF449
Control
NF449
Control
NF449
Control
NF023
COX1AQP4 IB4 Merge
COX2GFAP IB4 Merge
EpoxygenaseAQP4 IB4 Merge
a
b
c
d
Ar
te
rio
le
 
+c
ap
illa
ry
Ca
pi
lla
ry
Ar
te
rio
le
 
+c
ap
illa
ry
Supplementary Figure 5
Ca
pi
lla
ry
GFAP PGES MergeIB4
* * *
* * *
* * *
10 µm
10 µm
10 µm
10 µm
10 µm
Merge
No 1° control
10 µm
10 µm
10 µm
e
Merge
Merge
Merge
No 1° control
No 1° control
No 1° control
GFAP PLA2 MergeIB4
Supplementary Figure 6
10 µm
C
ap
illa
ry
a b
Supplementary Figure 7
c
%
 ∆
 in
 d
ia
m
et
er
Control FIPI
11 7
p=0.9
0
5
10
  D
ila
tio
n 
to
 P
G
E 2
 
(%
 b
as
el
in
e)
U46619
PGE2
FIPI
U46619
PGE2
5 min
10 % 
5 min
10 % 
bGFAP PLD2 MergeIB4c
d
AQP4 PLD1 MergeIB4
Supplementary Figure 8
a AQP4 PLD1 MergeIB4
C
ap
illa
ry
Ar
te
rio
le
C
ap
illa
ry
As
tro
cy
te
 s
om
a
GFAP PLD2 MergeDAPI*
*
*
*
*
*
*
*
*
50 µm
10 µm
10 µm
10 µm 10 µm
10 µm
10 µm
50 µm
Merge
No 1° controle
Merge
No 1° control
Merge
No 1° control
Merge
No 1° control
c%
 c
on
st
ric
tio
n 
0
5
10
15
Control BAPTA
Ca2+ chelator
44
P2X1
Control NF449
a
%
 c
on
st
ric
tio
n 
0
5
10
15
0
5
10
15
%
 c
on
st
ric
tio
n 
PLA2 and PLD2b
0
5
10
15
0
5
10
15
Control MAFP
Control L-NNAControl D-AP5
CAY10594
%
 c
on
st
ric
tio
n 
%
 c
on
st
ric
tio
n 
d e NOSNMDA
Supplementary Figure 9
1010 87
89 66 6
 1s  2s
 3s  5s 4s
50 µm
Alexa 594
Direction 
of flow
electrode
level
Before
puffing
 Start
puffing
Vessel
levela cb
d fe
g ih
Supplementary Figure 10
